Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Evodiamine** is a naturally occurring indole alkaloid and the primary bioactive component of the fruit Evodia rutaecarpa (also known as Euodia rutaecarpa), a traditional Chinese medicinal plant. It exhibits a range of pharmacological activities, including **antitumor, anti-inflammatory, cardioprotective, anti-atherosclerotic, anti-nociceptive, anti-gastric ulcer, and neuroprotective** effects. As a small molecule inhibitor, evodiamine is noted for its ability to suppress proliferation and migration of vascular smooth muscle cells (VSMCs), attenuate inflammation and oxidative stress, and modulate hormone secretion. Its antitumor effects have been demonstrated in multiple mouse cancer models, including colon, liver, lung, cervical, ovarian, pancreatic, breast, and lymphoma, with significant inhibition of tumor growth. The mechanism of action includes multi-target activity, with documented inhibition of the **PI3K/Akt signaling axis**, leading to reduced proliferation, migration, and inflammatory responses in vascular cells and cancer cells[1][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on evodiamine.